Per-Ola Carlsson

Per-Ola Carlsson is a Swedish clinical research entity and sole proprietorship led by Professor Per-Ola Carlsson of Uppsala University. The entity focuses on the development and clinical evaluation of regenerative medicine and cell-based therapies, particularly for the treatment of Type 1 Diabetes. It is primarily known for conducting investigator-initiated clinical trials in collaboration with academic institutions and biotech companies like NextCell Pharma. Key research areas include the use of mesenchymal stem cells (MSCs) to preserve beta-cell function and the optimization of islet transplantation techniques. The entity has been instrumental in advancing the ProTrans cell therapy through multiple Phase 2 clinical trials, including studies in pediatric populations. Its work integrates advanced medical cell biology with clinical endocrinology to translate innovative research into therapeutic applications.